Latest revenue
$317.0M
as of 2026-03-31
Latest net income
$13.8M
as of 2026-03-31
Net margin
4.4%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Electromedical & Electrotherapeutic Apparatus (37 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Fair value · DCF
DCF: 10-year forecast of free cash flow, discounted at the company's WACC, with a Gordon-growth terminal at year 10. FCF is proxied by last fiscal-year net income (proper FCF needs CFO − CapEx by year, which we don't store yet). Drag the slider to test your own growth thesis — the dominant assumption in any DCF is what comes next, not what the math does with it. Beta defaults to 1.0 when not reported.
Community sentiment
Where do you think CNMD is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $1.08B
- Enterprise value
- $1.92B
- P/E (trailing)
- 23.0×
- Forward P/E
- —
- P/B
- 1.07×
- Dividend yield
- 1.1%
- 52-wk high
- $60.35
- 52-wk low
- $32.13
- Beta
- —
- Shares out
- 30.8M
5-year trend
What this company does
CONMED CORPORATION Item 1. Business Forward Looking Statements This Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (“Form 10-K”) contains certain forward-looking statements (as such term is defined in the Private Securities Litigation Reform Act of 1995) and information relating to CONMED Corporation (“CONMED”, the “Company”, “we” or “us” — references to “CONMED”, the “Company”, “we” or “us” shall be deemed to include our direct and indirect subsidiaries unless the context otherwise requires) which are based on the beliefs of our management, as well as assumptions made by and information currently available to our management. When used in this Form 10-K, the words…
AI summary unavailable — showing raw filing excerpt
Generated from CNMD's filing dated 2026-02-17
Key risks
Item 1A. Risk Factors An investment in our securities, including our common stock, involves a high degree of risk. Investors should carefully consider the specific factors set forth below as well as the other information included or incorporated by reference in this Form 10-K. See “Forward Looking Statements”. (i) Risks Related to Our Business and the Medical Device Industry Our financial performance is dependent on conditions in the healthcare industry and the broader economy. Our business and financial performance could be adversely affected, directly or indirectly, by a potential economic downturn. The results of our business are directly tied to the economic conditions in the healthcare…
AI summary unavailable — showing raw filing excerpt
Generated from CNMD's filing dated 2026-02-17
Profitability
Gross margin
54.6%
2.7%Operating margin
7.5%
51.3%Net margin
3.4%
66.2%Return on equity
4.9%
64.5%Return on assets
2.0%
64.8%Leverage
Debt / equity
1.42×
1.5%Long-term debt / equity
0.87×
7.8%Debt / assets
58.6%
0.6%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $317.0M | -1.3% | $13.8M | +129.1% | 4.4% |
Q4 2025 2025-12-31 | $373.2M | +7.9% | $16.7M | -50.4% | 4.5% |
Q3 2025 2025-09-30 | $337.9M | +6.7% | $2.9M | -94.2% | 0.8% |
Q2 2025 2025-06-30 | $342.3M | +3.1% | $21.4M | -28.5% | 6.3% |
Q1 2025 2025-03-31 | $321.3M | +2.9% | $6.0M | -69.4% | 1.9% |
Q4 2024 2024-12-31 | $345.9M | — | $33.8M | — | 9.8% |
Q3 2024 2024-09-30 | $316.7M | +4.0% | $49.0M | +209.3% | 15.5% |
Q2 2024 2024-06-30 | $332.1M | +4.5% | $30.0M | +118.3% | 9.0% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Electromedical & Electrotherapeutic Apparatus · SIC 3845
Your notes
Keep private notes on CNMD — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$299.5K
Net activity
−$299.5K
Distinct insiders
3
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns CNMD
Institutional value
$591.7M
Total shares held
17.2M
Distinct holders
139
-126 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 4.8M | $170.6M | +50.5K (+1.1%) | Added |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.1M | $73.4M | — | New |
| 3 | DIMENSIONAL FUND ADVISORS LP | 1.4M | $49.2M | +80.1K (+6.1%) | Added |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 1.4M | $48.9M | — | New |
| 5 | SEI INVESTMENTS CO | 1.0M | $35.5M | +23.7K (+2.4%) | Added |
| 6 | COOKE & BIELER LP | 987.8K | $34.9M | +120.0K (+13.8%) | Added |
| 7 | Capital Research Global Investors | 925.4K | $32.7M | +0 (+0.0%) | No change |
| 8 | Allspring Global Investments Holdings, LLC | 582.7K | $20.7M | +166.3K (+39.9%) | Added |
| 9 | Bank of New York Mellon Corp | 289.2K | $10.2M | +4.3K (+1.5%) | Added |
| 10 | Tributary Capital Management, LLC | 249.0K | $8.8M | -19.9K (-7.4%) | Trimmed |
| 11 | PRINCIPAL FINANCIAL GROUP INC | 210.7K | $7.4M | +25.9K (+14.0%) | Added |
| 12 | VANGUARD FIDUCIARY TRUST CO | 201.6K | $7.1M | — | New |
| 13 | Invesco Ltd. | 166.6K | $5.9M | -17.4K (-9.5%) | Trimmed |
| 14 | ENVESTNET ASSET MANAGEMENT INC | 141.0K | $5.0M | -2.7K (-1.9%) | Trimmed |
| 15 | Legal & General Group Plc | 133.7K | $4.7M | -13.8K (-9.3%) | Trimmed |
| 16 | UBS Group AG | 116.9K | $4.1M | +71.8K (+158.8%) | Added |
| 17 | WEDGE CAPITAL MANAGEMENT L L P/NC | 114.4K | $4.0M | -16 (-0.0%) | Trimmed |
| 18 | Public Sector Pension Investment Board | 110.8K | $3.9M | +3.4K (+3.2%) | Added |
| 19 | JANE STREET GROUP, LLC | 96.9K | $3.4M | -179.9K (-65.0%) | Trimmed |
| 20 | WELLS FARGO & COMPANY/MN | 96.4K | $3.4M | -74.4K (-43.6%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once CNMD's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.